Phase 2 Study With PQR309 in Relapsed or Refractory Lymphoma Patients
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The main goal of this study is to determine the Maximum Tolerated Dose (MTD) and the
Recommended Phase II Dose (RP2D) as well as preliminary antitumor activity of PQR309
administered orally, as once daily capsules continuously and on intermittent schedule, in
patients with relapsed or refractory lymphomas.
Phase:
Phase 2
Details
Lead Sponsor:
PIQUR Therapeutics AG
Collaborators:
Charite University, Berlin, Germany University Hospital Freiburg University Hospital Munich University Hospital, Basel, Switzerland University of Stuttgart